Abstract
Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine kinase with varied number of actions in cellular signalling systems making it an emerging target for diseases such as diabetes mellitus, cancer, chronic inflammation, bipolar affective disorders and Alzheimers disease. Various efforts have produced many potent small molecule inhibitors of GSK-3, which are being tested for modulation of glycogen metabolism, gene transcription, apoptosis and enhancement of insulin-stimulated glucose transport. Majority of the reported inhibitors show their inhibitory effects towards other phylogenetically related kinases also, like cyclin dependant kinases (CDKs). Thus it is important to develop inhibitors that can inhibit GSK-3 selectively. Rational approaches based on the knowledge of the receptor are best suited to address the selectivity problem. Several crystal structures of GSK-3β with different ligands are being reported. These are providing the necessary clues regarding the interaction in the ligand binding domain. Several molecular docking efforts are being taken up to identify the clues for enhancing selectivity towards GSK-3. In this review we present current efforts and future opportunities in designing selective GSK-3 inhibitors.
Keywords: Insulin Signaling Pathway, FRATide peptide, X-Ray Crystallography, Maleimides, Paullones, Cyclin dependant kinase
Current Protein & Peptide Science
Title: Structure-Based Approaches in the Design of GSK-3 Selective Inhibitors
Volume: 8 Issue: 4
Author(s): Dhilon S. Patel, Nigus Dessalew, Pansy Iqbal and Prasad V. Bharatam
Affiliation:
Keywords: Insulin Signaling Pathway, FRATide peptide, X-Ray Crystallography, Maleimides, Paullones, Cyclin dependant kinase
Abstract: Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine kinase with varied number of actions in cellular signalling systems making it an emerging target for diseases such as diabetes mellitus, cancer, chronic inflammation, bipolar affective disorders and Alzheimers disease. Various efforts have produced many potent small molecule inhibitors of GSK-3, which are being tested for modulation of glycogen metabolism, gene transcription, apoptosis and enhancement of insulin-stimulated glucose transport. Majority of the reported inhibitors show their inhibitory effects towards other phylogenetically related kinases also, like cyclin dependant kinases (CDKs). Thus it is important to develop inhibitors that can inhibit GSK-3 selectively. Rational approaches based on the knowledge of the receptor are best suited to address the selectivity problem. Several crystal structures of GSK-3β with different ligands are being reported. These are providing the necessary clues regarding the interaction in the ligand binding domain. Several molecular docking efforts are being taken up to identify the clues for enhancing selectivity towards GSK-3. In this review we present current efforts and future opportunities in designing selective GSK-3 inhibitors.
Export Options
About this article
Cite this article as:
Dhilon S. Patel , Nigus Dessalew , Pansy Iqbal and Prasad V. Bharatam , Structure-Based Approaches in the Design of GSK-3 Selective Inhibitors, Current Protein & Peptide Science 2007; 8(4) . https://dx.doi.org/10.2174/138920307781369409
DOI https://dx.doi.org/10.2174/138920307781369409 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Modulating Effects of Endogenous Substances on Drug Metabolising Enzymes and Implications for Inter-Individual Variability and Quantitative Prediction
Current Drug Metabolism TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets The Role of Plant-Derived Compounds in Managing Diabetes Mellitus: A Review of Literature from 2014 To 2019
Current Medicinal Chemistry Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Screening Haemostasis – Looking for Global Assays: The Overall Haemostasis Potential (OHP) Method – A Possible Tool for Laboratory Investigation of Global Haemostasis in Both Hypo- and Hypercoagulable Conditions
Current Vascular Pharmacology Effects of Cichorium Intybus Linn on Blood Glucose, Lipid Constituents and Selected Oxidative Stress Parameters in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Disease among Patients with Diabetes: The Current Scenario in Saudi Arabia
Current Diabetes Reviews Recent Advances in the Medicinal Chemistry of Aurones
Current Medicinal Chemistry Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease
Current Vascular Pharmacology Engineering of Therapeutic Proteins Production in Escherichia coli
Current Pharmaceutical Biotechnology Control of Menopausal Transition through Physical Exercises
Current Women`s Health Reviews Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Methicillin-Resistant <i>Staphylococcus aureus</i>: Treatment with Cultures of Non Drug-Resistant <i>Staphylococcus epidermidis</i>
Recent Patents on Anti-Infective Drug Discovery Applications and Limitations of Genetically Modified Mouse Models in Drug Discovery and Development
Current Drug Metabolism Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Current Stem Cell Research & Therapy Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design